Speaker illustration

Mr Qidi Ying

Royal Perth Hospital, Perth (Australia)

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipid-Lowering Agents

Session: Congress committee e-posters choice in pharmacology and pharmacotherapy


ESC 365 is supported by

logo Novo Nordisk